CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
作者信息
Holzinger Astrid, Abken Hinrich
机构信息
Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
Clinic I Internal Medicine, University Hospital Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
出版信息
Cancer Immunol Immunother. 2017 Nov;66(11):1505-1507. doi: 10.1007/s00262-017-2045-4. Epub 2017 Jul 28.
Abstract
摘要
相似文献
1
CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
Cancer Immunol Immunother. 2017 Nov;66(11):1505-1507. doi: 10.1007/s00262-017-2045-4. Epub 2017 Jul 28.
2
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Sci China Life Sci. 2016 Apr;59(4):340-8. doi: 10.1007/s11427-016-5027-4. Epub 2016 Mar 11.
3
Armed T cells with CAR for cancer immunotherapy.
Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15.
4
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28.
5
Strategies to genetically engineer T cells for cancer immunotherapy.
Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2.
6
CARs in the Lead Against Multiple Myeloma.
Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2.
7
The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors.
Am Soc Clin Oncol Educ Book. 2018 May 23;38:830-837. doi: 10.1200/EDBK_200773.
8
Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Immunotherapy. 2009 Nov;1(6):905-12. doi: 10.2217/imt.09.69.
9
Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.
Arch Immunol Ther Exp (Warsz). 2010 Jun;58(3):165-78. doi: 10.1007/s00005-010-0074-1. Epub 2010 Apr 6.
10
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Mol Ther. 2017 Sep 6;25(9):2189-2201. doi: 10.1016/j.ymthe.2017.06.008. Epub 2017 Jul 1.
引用本文的文献
1
Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions.
Cancer Cell Int. 2025 Aug 23;25(1):313. doi: 10.1186/s12935-025-03938-0.
2
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges.
Nat Rev Gastroenterol Hepatol. 2025 Apr 14. doi: 10.1038/s41575-025-01062-y.
3
Immunotherapy in gastrointestinal cancers: current strategies and future directions - a literature review.
Ann Med Surg (Lond). 2025 Jan 9;87(1):151-160. doi: 10.1097/MS9.0000000000002757. eCollection 2025 Jan.
4
Carcinoembryonic Antigen Expression in Human Tumors: A Tissue Microarray Study on 13,725 Tumors.
Cancers (Basel). 2024 Dec 3;16(23):4052. doi: 10.3390/cancers16234052.
5
CAR T cells in solid tumors and metastasis: paving the way forward.
Cancer Metastasis Rev. 2024 Dec;43(4):1279-1296. doi: 10.1007/s10555-024-10213-7. Epub 2024 Sep 24.
6
CAR-T cell therapy in advanced thyroid cancer: from basic to clinical.
Front Immunol. 2024 Jun 7;15:1411300. doi: 10.3389/fimmu.2024.1411300. eCollection 2024.
7
Car T Cells in Solid Tumors: Overcoming Obstacles.
Int J Mol Sci. 2024 Apr 10;25(8):4170. doi: 10.3390/ijms25084170.
8
Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells.
Front Immunol. 2023 Dec 15;14:1302354. doi: 10.3389/fimmu.2023.1302354. eCollection 2023.
9
"Hurdles race for CAR T-cell therapy in digestive tract cancer".
Immunol Rev. 2023 Nov;320(1):100-119. doi: 10.1111/imr.13273. Epub 2023 Sep 11.
10
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
Arch Immunol Ther Exp (Warsz). 2023 Aug 11;71(1):19. doi: 10.1007/s00005-023-00684-x.
本文引用的文献
1
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28.
2
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Metastatic Colorectal Cancers.
Mol Ther. 2017 May 3;25(5):1248-1258. doi: 10.1016/j.ymthe.2017.03.010. Epub 2017 Mar 31.
3
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.
Clin Cancer Res. 2015 Jul 15;21(14):3149-59. doi: 10.1158/1078-0432.CCR-14-1421. Epub 2015 Apr 7.
4
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol Ther. 2011 Mar;19(3):620-6. doi: 10.1038/mt.2010.272. Epub 2010 Dec 14.
Zotero 插件